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Summary. Acinetobacter baumannii is an opportunistic bacterial pathogen that is the major cause of hospital-acquired infec-
tions. It has been shown that A. baumannii with high biofilm formation increases the risk of acquiring infection. In this study, 
the prevalence of virulence genes involved in biofilm formation was determined in 225 A. baumannii clinical isolates from three 
hospitals in Thailand. Most of the isolates were multidrug-resistant A. baumannii strains (86.2%). Among all isolates, 76.9% 
(173/225) showed biofilm formation ability. The association between biofilm forming ability and gentamicin resistance was 
found (P < 0.05). The presence of virulence genes, epsA, bap, ompA, bfmS and blaPER-1 genes, was investigated by PCR. The 
prevalence of ompA, bfmS, bap, blaPER-1 and epsA genes among the isolated strains was 84.4%, 84%, 48%, 30.2%, respectively. 
Biofilm formation related genes, ompA and bap were associated with multidrug-resistant A. baumannii strains. The result of this 
study revealed that a high prevalence of biofilm-forming phenotypes among A. baumannii strains obtained from different 
hospitals. Effective strategies to prevent infection due to A. baumannii that produce biofilms are therefore needed. [Int Microbiol 
19(2):121-129 (2016)]
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Introduction
Acinetobacter baumannii is a Gram-negative bacterium that 
causes a variety of diseases. It exists especially in health care 
settings such as hospital environments. The emergence of 
multidrug-resistant A. baumannii strains is considered as a 
major and immediate threat to public health worldwide. One 
of the major factors involved in bacterial resistance to antimi-
crobials, chronic infections or survival in varying environ-
ments is the ability to form biofilms. There are a variety of 
virulence determinants involved in biofilm formation of A. 
baumannii. This bacterium produces a molecule called the 
biofilm-associated protein (BAP), which is encoded by the 
bap gene [21]. BAP contributes to the initiation of biofilm 
production after A. baumannii attaches to a particular surface 
[14,19]. The outer membrane protein (OmpA), encoded by 
the ompA gene, is an adhesion molecule that functions during 
the attachment to human epithelial cells and induces biofilm 
formation [10]. Acinetobacter baumannii produces a polysac-
charide export outer membrane protein, called exopolysac-
Int. MIcrobIol. Vol. 19, 2016 THUMMEEPAK ET AL.122
charide or EPS, which is encoded by epsA. EPS accumulates 
on the cell surface and provides protection to the cells against 
the harsh external environment [27,31]. Production of EPS is 
involved in the aggregation of bacteria which is associated 
with biofilm formation in many bacteria [33]. In addition, Lee 
et al. [16] have shown that the ability of clinical isolates of A. 
baumannii to form biofilm and to adhere to respiratory epithe-
lial cells is enhanced by the presence and expression of the 
blaPER-1 gene. Recently, a two-component system (BfmS/
BfmR) has been identified which is needed for biofilm forma-
tion on polystyrene surfaces [32]. The A. baumannii 17978 
type strain, with an inactivated bfmS, showed a reduction in 
biofilm formation [17]. To date, the mechanisms by which 
virulence determinants contribute to biofilm formation and 
antibiotic resistance still remain unclear. The aim of this study 
was to determine the association of biofilm formation, antibi-
otic resistance phenotype and virulence genes in A. bauman-
nii clinical isolates.
Materials and methods
Bacterial isolation and identification of Acinetobacter 
baumannii. A total of 225 individual clinical isolates was collected from 3 
tertiary hospitals in 3 different provinces in Thailand over the 12 month period 
from November 2013 to October 2014. All A. baumannii isolates were col-
lected from multiple collection sites, including sputum, urine, pus, blood, 
pleural fluid, ascetic fluid and wound. All isolates were identified as A. bau-
mannii by using biochemical tests, detecting of 16S rRNA gene [22] and the 
intrinsic bla
OXA-51
 gene [1,5]. Acinetobacter baumannii ATCC 19606 was used 
as a control.
Determination of antimicrobial susceptibilities. The antibiotic 
susceptibility was analyzed by the disc diffusion method (Oxoid). The concen-
trations of the antibiotics in the discs (expressed in µg) were: amikacin (30), 
cefotaxime (30), ceftazidime (30), ceftriaxone (30), cefepime (30), ciprofloxa-
cin (5), gentamicin (10), imipenem (10), meropenem (10), trimethoprim/sulfa-
methoxazole (1.25/23.75), tetracycline (30), cefoperazone/sulbactam (105), 
and piperacillin/tazobactam (100/10). The Petri dishes were incubated at 35 
°C for 24 h. The zones of inhibition determined whether the microorganism 
was susceptible, intermediately resistant, or resistant to each antibiotic. The 
results were interpreted according to the CLSI [6]. 
Detection of biofilm formation. Quantitative microtiter plate as-
says for biofilm formation were performed as described by Brossard and 
Campagnari [4] with some modification. One hundred µl of 108 CFU/ml of 
A. baumannii and an equal volum of 2× Luria Bertain (LB) broth supple-
mented with 20% glucose were added to each well in 96-well polystyrene 
microtiter plates (Nunc, Denmark). The plates were incubated overnight at 
37 °C. After incubation, the cultures were gently removed. The wells were 
washed three times with phosphate buffered saline. The adherent cells were 
fixed with absolute methanol for 10 min and stained with 0.4 % crystal violet 
for 15 min, and washed three times with sterile distilled water and then air-
dried.  Afterward, the plates were filled with 250 μl of 33 % acetic acid for 
15 min. The absorbance at OD
595
 nm was determined. All experiments were 
performed in three independent assays each repeated in triplicate. The mean 
optical density at 595 nm (OD
595
) of the non-biofilm producer E. coli DH5α 
was used as the OD cut-off value (ODc). The OD results of all tested strains 
were divided into the following four groups: (I) OD ≤ ODc = non biofilm 
Producer; (II) ODc < OD ≤ 2× ODc = weak biofilm Producer; (III) 2× ODc < 
OD ≤ 4 × ODc = moderate biofilm Producer; and (IV) 4× ODc < OD = strong 
biofilm producer [35].
Table 1. List of primers for detection of virulence genes used in this study
Target gene Primer sequence Tm (oC) References
epsA AGCAAGTGGTTATCCAATCGACCAGACTCACCCATTACAT 50 [31]




bap TACTTCCAATCCAATGCTAGGGAGGGTACCAATGCAGTTATCCACTTCCAATGATCAGCAACCAAACCGCTAC 65 [12]
bfmS TTGCTCGAACTTCCAATTTATTATACTTATGCAGGTGCTTTTTTATTGGTC 53 [17]
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Detection of virulence genes by PCR. The presence of epsA, bap, 
ompA, bfmS and blaPER-1 genes was detected with primers as shown in Table 1. 
DNA was extracted from all the isolates by boiling. Each PCR was performed 
in triplicate in a thermocycler with a PCR condition as described previously 
[12,16,17,31]. PCR products were analyzed by electrophoresis in 1% agarose 
gel containing 0.5 µg/ml ethidium bromide. 
Statistical analyses. All statistical analyses were performed using 
Stata (Stata12.0 Corporation, USA). Non-parametric Kruskal–Wallis test and 
Dunn’s test were performed to compare the median value among multiple 
groups. The difference of biofilm biomass between two groups was compared 
by using Mann–Whitney U test. Fisher’s exact test was used to access differ-
ences between frequencies. P-values < 0.05 were considered to be statisti-
cally significant.
Results
Biofilm formation by clinical Acinetobacter 
baumannii isolates. All A. baumannii isolates were 
tested for the ability to form biofilms. The mean OD
595 
value 
for the negative control Escherichia coli DH5α was 0.221 ± 
0.072 and this value was used as the optical density cut-off 
value (ODc). The classification of biofilm based on ODc re-
vealed that OD
595 
≤ 0.221 = non-biofilm; 0.221 < OD
595
 ≤ 
0.442 = weak biofilm; 0.442 < OD
595
 ≤ 0.884 = moderate bio-
film; OD
595
 > 0.884 = strong biofilm. Among all isolates, 
23.1% were non-biofilm producers, while the majority were 
biofilm producers (76.9%). The number of weak biofilm pro-
ducers was 46 (20.4%), with 74 moderate biofilm producers 
(32.9 %) and 53 strong biofilm producers (23.6%). The me-
dian OD
595
 and interquartile range (IQR) value for non-bio-
film formers was 0.148 (0.091, 0.187), for weak biofilm form-
ers, 0.332 (0.297, 0.404), moderate biofilm formers, 0.620 
(0.494, 0.720) and strong biofilm formers, 1.170 (0.991, 
1.430). We found that 173 of 225 isolates (76.9 %) were more 
capable of forming biofilms than the DH5α strain with a me-
dian biofilm biomass of 0.624 (0.432, 0.949). 
Distributions of biofilm-formers in various 
sources and wards. All 225 A. baumannii isolates were 
obtained from sputum (81.8 %), pus (7.5 %), urine (4.9 %) 
and other specimens (obtained from skin, blood, coccyx, cath-
eter or pleural fluid) (5.8%). The proportion of strong biofilm 







Fig. 1. Characterization of biofilm production in 225 clinical isolates of Acinetobacter baumannii. (A and C) Relative composition of each biofilm formation 
level from different sources and wards. Each individual bar represents the proportion that contains different biofilm status. (B and D) The median of biofilm 
biomass (OD
595
) in clinical isolates from different sources and wards. Each data point is representative of the mean OD
595
 of independent triplicates of each 
individual isolates. The line bar (black) represents the median of OD
595
. ICU, Intensive Care Unit; MED, Medicine; SUR, Surgical; and Other: monk ward, 
coronary care unit, trauma ward, pediatric ward and outpatient department. Asterisks (*) indicate differences that are statistically significant; Kruskal–Wallis 
test followed by Dunn’s multiple comparison post-test; P < 0.05.
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sputum, 32.6%, and pus, 11.8% (Fig. 1A). The comparison of 
biofilm biomass (OD
595
) among the various sources of speci-
mens by the Kruskal–Wallis test showed significant differ-
ences among the groups (P < 0.05). The median (IQR) of 
isolates obtained from urine [0.799 (0.489, 1.300)] and other 
specimens [0.720 (0.416, 1.330)] were higher than pus [0.186 
(0.065, 0.423)] with P-values less than 0.05 (Dunn’s test) 
(Fig. 1B).
The prevalence of strong biofilm producers was similar 
among the strains recovered from different wards, ranging 
from 18.8% to 27.3% (Fig. 1C). However, analysis of the bio-
film forming capacity of the isolates obtained from various 
wards revealed a statistically significant difference in OD
595 
between medical and surgical wards (P < 0.05; Kruskal–Wal-
lis and Dunn’s tests) (Fig. 1D).
Association of biofilm-forming capability with 
antibiotic resistance phenotype. All isolates were 
tested for their antibiotic susceptibility toward 13 antibiotics. 
The majority of isolates were resistant to ciprofloxacin 
(84.4%). The A. baumannii isolated strains were also resistant 
to amikacin (54.2%), cefotaxime (76.9%), ceftazidime 
(82.2%), ceftriaxone (81.3%), cefepime (67.6%), gentamicin 
(68%), imipenem (79.6%), meropenem (78.7%), trime-
thoprim/sulfamethoxazole (54.2%), tetracycline (62.7%) ce-
foperazone/sulbactam (20.4%) and piperacillin/tazobactam 
(79.1%). All isolates were defined as being multidrug resis-
tant A. baumannii (MDRAB) when there was resistance to 
more than three antibiotic classes. The incidence of MDRAB 
was 86.2 % (194/225). Among 194 of MDRAB isolates, 150 
(77.3 %) were biofilm-forming strains while 74.2 % (23/31) 
of non-MDRAB also produced biofilms (P = 0.654; Fisher’s 
exact test). This finding was supported by analysis of the me-
dian OD
595
 among three drug resistance patterns (Fig. 2). As 
illustrated in Fig. 2B, the median (IQR) of non-MDRAB, 
MDRAB and XDRAB were 0.500 (0.157, 0.990), 0.461 
(0.245, 0.794) and 0.605 (0.444, 0.770), respectively. There 
was no significant difference among the groups (P = 0.536; 
Kruskal–Wallis test). 
The association between biofilm forming ability and indi-
vidual drug resistance of A. baumannii was evaluated. The 
resistance rates of most antibiotics were found to be similar in 
both biofilm-forming and non-biofilm forming groups with a 
P-value ranging from 0.191 to 1.000. Of the 153 gentamicin 
resis tant isolates, 125 (81.7%) strains were biofilm producers 
while only 48 of 72 (66.7%) of gentamicin susceptible strains 
were biofilm producers (P = 0.017; Fish er’s exact test). This 
result was also confirmed by using Mann–Whitney U-test to 
compare the me dian (IQR) of OD
595
 between drug resistant 
and susceptible groups. In A. baumannii that resistance to 
gentamicin had a significantly higher ability to build biofilms 
when compared with gentamicin sensitive groups (P < 0.05) 
(Table 2). In contrast, the tetracycline susceptible isolates 
tended to form greater biofilm biomass than resistant strains 
(P < 0.001; Mann–Whitney U-test) (Table 2). However, the 







Fig. 2. Biofilm produced (OD595) on polystyrene by 225 isolates of Acinetobacter baumannii with different drug susceptibility patterns. (A) Biofilm formation 
of non MDR, MDR and XDR strains are represented by blue, green and orang bars, respectively. Data shown are the means of a triplicate plus standard 
deviation. (B) The open circle dot represents the mean of independent triplicate of each isolate. The line bar (black) indicates the median OD
595
 of each group 
with differences antibiotic resistance pattern. The dashed lines correspond to the cut-off value (ODc).
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strains was similar to that in resistant strains (82.1 vs. 73.8%) 
(P = 0.191; Fish er’s exact test). For other antibiotics, no sta-
tistical correlation was observed (Table 2).
Relationship of biofilm production and the 
presence of different virulence genes. Polymerase 
chain reaction (PCR) was utilized to investigate the presence of 
the epsA, bap, ompA, bfmS and blaPER-1 genes in all A. bauman-
nii isolates. The electrophoresis analysis showed that the ampli-
con sizes of epsA, bap, ompA, bfmS and blaPER-1 genes were 
451, 531, 927, 1225 and 1428 bp, respectively (data not shown). 
The most common virulence genes identified were ompA 
(84.4%) and bfmS (84%). The prevalence of genes bap, blaPER-1 
and epsA genes among the isolated strains was 48%, 30.2% and 
22.2%, respectively. Among the 225 A. baumannii isolates, all 
5 virulence genes were present in 9 isolates (4%). The associa-
tion between biofilm formed on the microtiter plate and the 
presence of virulence genes was also tested, using Mann–Whit-
ney U test. The presence or absence of epsA, bfmS and blaPER-1 
was not associated with the biofilm biomass (P > 0.05; Fig. 
3C–E). The strains lacking bap or ompA genes form stronger 
biofilms than isolates carrying bap or ompA (P < 0.05; Fig. 
3A,B). However, the frequency of epsA, bfmS, blaPER-1, bap 
and ompA was no significant difference between biofilm pro-
ducers and non-biofilm producers with a P-value more than 
0.05 (0.253, 0.281, 0.393, 0.117 and 0.199, respectively, Fish-
er's exact test). We also examined the differences among vari-
ous virulence gene patterns in their ability to produce biofilm. 
The number of virulence genes contributed to the trend of de-
creased biofilm biomass, but this was not statistically signifi-
cant (P > 0.05; Kruskal–Wallis test) (Fig. 3F). 
Correlation between virulence genes and anti-
biotic resistance patterns. The association between 
the presence of virulence genes and MDR status was evalu-
ated. There is no statistical relationship between MDRAB and 
any of A. baumannii harbored epsA, bfmS and blaPER-1 genes 
(Table 3). The genes encoding BAP were present at a higher 
frequency in MDRAB than in non-MDRAB strains (P < 0.05) 
(Table 3). Gene ompA was present in 169 of 194 (87.1%) 
MDRAB isolates versus only 21 of 31 (67.74%) of non-
MDRAB strains (P < 0.05). The correlation between the pres-
ence of ompA and resistance to thirteen antimicrobials was 
also evaluated. The strains carrying ompA were found at a 
higher prevalence of resistance at least one drug from five 
antimicronial categories including aminoglycosides, ce-
phems, fluoroquinolones, carbapenems and penicillins + 
β-lactamase inhibitors than the strains without this gene (P < 0.05; 
(Table 4). The number of virulence genes present in the iso-
lates was a statistically significant predictor of multiple drug 
resistance phenotype (risk ratio, 1.16; 95% CI, 1.11 to 2.42; P 
= 0.011). 
Discussion
Biofilm production in clinical Acinetobacter 
baumannii. The ability of bacteria to form biofilm is regard-
ed as an important virulence factor which plays a significant role 
in the bacteria’s persistence and antibiotic resistance [20]. In our 
work, we determined the biofilm formation, antibiotic suscepti-
bility patterns and virulence genes among 225 clinical isolates. 
We found that more than seventy percent of studied A. bauman-
nii showed biofilm formation ability. Our findings agree closely 
with those previously reported in [8] which showed that 75% of 
clinical A. baumannii isolates were positive for biofilm produc-
tion, although different criteria were used to interpret biofilm 
status.
Correlation of biofilm among specimen types 
and wards. Clinical isolates recovered from urine and 
other sources (skin tissue, blood, coccyx, catheter and pleural 
fluids) were shown to have a significantly higher ability to 
form biofilms compared to those recovered from a pus 
source. This result agrees with a previous study which re-
ported that A. baumannii obtained from urine specimens pro-
duced biofilms with a greater biomass [8]. Urinary tract 
pathogens may have abilities to adhere and form biofilms in 
flowing environments, resulting in persistent infections. Our 
analysis also found significant differences in biofilm produc-
ing capacity among isolates from various hospital wards. The 
ability to form a biofilm on an abiotic of clinical isolates pro-
vides biofilm associated infection due to the attachment and 
colonization on medical device surfaces, such as urinary 
catheters [7].
Biofilm and antibiotic resistance. Acinetobacter 
baumannii is a major global health problem. In the past de-
cade, high prevalence rates of MDRAB clinical isolates have 
been reported worldwide, ranging from 21–95% [15,18,34]. 
Similarly to other reports, we observed a high prevalence rate 
of MDRAB in this study. Previous studies reported that the 
MDR phenotype of pathogens as well as A. baumannii was 
linked to biofilm producing ability [13,28]. In contrast, our 
results indicate that the MDR and XDR phenotype has no as-
sociation with biofilm producing ability. The ability of bacte-
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ria to form biofilm may be associated with antibiotic resis-
tance at the level of the individual. For example, Naparstek et 
al. [23] studied the biofilm production in Klebsiella pneu-
moniae and they concluded that high-level gentamicin resis-
tant strains show greater biofilm biomass compared with 
populations which have low-level resistance (median value of 
0.15 versus 0.07, respectively) [23]. In 2016, Duarte et al. ob-
served that A. baumannii isolates resistant to gentamicin and 
tobramycin were more frequently able to form biofilms than 
susceptible strains [8]. In our study we found that strains pos-
itive for biofilm formation were more frequently resistant to 
gentamicin. 
In addition, the biofilm biomass of gentamicin resistance 
isolates was greater than susceptible groups (Table 2). Similar 
Table 3. Relationship between virulence genes and antibiotic susceptibility patterns in all tested Acinetobacter baumannii isolates
The present of virulence genes
All A. baumannii isolates n = 225 (%)
P-valueaNon MDRAB (n = 31) MDRAB (n = 194)
bap 8 (25.81) 100 (51.55) 0.011*
ompA 21 (67.74) 169 (87.11) 0.013*
epsA 7 (22.58) 43 (22.16) 1.000
bfmS 26 (83.87) 163 (84.02) 1.000
blaPER-1 8 (25.81) 60 (30.93) 0.676
aP-values represent the comparison between non MDRAB and MDRAB groups (Fisher’s exact test; P < 0.05). An asterisk (*) 
indicates the statistical significance (P-value < 0.05).
Table 2. Correlation between biofilm biomass (OD
595
) and drug resistance phenotype in all Acinetobacter baumannii isolates
Antibiotics susceptibility
Median (IQR) of OD
595
P-valueaSusceptible Resistant
amikacin 0.440 (0.252, 0.790) 0.496 (0.246, 0.890) 0.208
cefotaxime 0.481 (0.209, 0.921) 0.470 (0.277, 0.790) 0.942
ceftazidime 0.494 (0.211, 0.980) 0.470 (0.248, 0.790) 0.651
ceftriaxone 0.531 (0.252, 0.970) 0.465 (0.246, 0.790) 0.386
cefepime 0.515 (0.210, 0.830) 0.463 (0.258, 0.803) 0.893
ciprofloxacin 0.489 (0.157, 0.970) 0.471 (0.252, 0.790) 0.926
gentamicin 0.400 (0.154, 0.769) 0.515 (0.297, 0.860) 0.012*
imipenem 0.541 (0.279, 0.900) 0.461 (0.241, 0.790) 0.386
meropenem 0.510 (0.278, 0.860) 0.465 (0.241, 0.799) 0.648
TMX/SXT 0.521 (0.297, 0.901) 0.445 (0.237, 0.720) 0.166
tetracycline 0.692 (0.348, 1.055) 0.444 (0.213, 0.669) <0.001*
cefoperazone/sulbactam 0.461 (0.244, 0.814) 0.553 (0.268, 0.890) 0.303
piperacilin/tazobactam 0.462 (0.252, 0.790) 0.473 (0.246, 0.820) 0.928
aP-values represent the comparison of median OD
595
 of bacterial strains between two groups (Mann–Whitney U-test). An asterisk (*) 
indicates the significance (P-value < 0.05).
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results have also been reported for Pseudomonas aeruginosa, 
where strains characterized as gentamicin resistant showed a 
significant increase in biofilm production when compared to 
susceptible strains [30]. Our analysis of biofilm forming abil-
ity with gentamicin resistance phenotypes has provided posi-
tive statistical association findings. 
We proposed that this phenotypic correlation may be due 
to biofilm-associated and gentamicin resistance determinants 
are co-located on the same plasmid or genomic island. How-
ever, we found only an association between negative biofilm 
forming ability and tetracycline resistance phenotype. This 
finding differs from previous study in which a negative cor-
relation between biofilm forming ability and antibiotic resis-
tance to each of 20 antibiotics was reported [24]. The mecha-
nism of this association was not clear but the expression of 
blaTEM-1 was reported to block biofilm formation via the bacte-
rial adhesion interfering [11].
Biofilm and virulence genes. We found that A. bau-
mannii isolates harboring virulence genes did not promote 
biofilm forming ability on polystyrene, while the presence of 
bap or ompA showed an inverse correlation. Although many 
reports have demonstrated that biofilm associated genes, in-
cluding bap, ompA, epsA, bfmS and blaPER-1, were responsible 
for the biofilm development of only certain selected A. bau-
mannii strains [10,14,17,19,21,27,31,32], these reports did 
not fully characterize their functions in a diverse range of 
other strains and on different surfaces. Moreover, blaPER-1 and 
ompA were not over-expressed in biofilm cells as previously 
analyzed indicating that these genes are not fully required for 
biofilm production in some strains [25,26]. This suggests that 
other key factors or strain-dependent variations contribute to 
biofilm forming phenotypes in diverse biotic or abiotic sur-
faces. [3,9].
Virulence gene and MDR phenotype. Although, 
the OmpA of A. baumannii was found to be essential for the 
development of biofilms and attachment to human epithelial 
cells [10]. Its involvement in antimicrobial resistance pheno-







Fig. 3. The correlation between in vitro biofilm formation and virulence genes. (A–E) Biofilm forming capacity (OD
595
) of bacteria harboring and not harboring 
individual virulence genes. Asterisks (*) indicate differences that are statistically significant; Mann–Whitney U-test. (F) OD
595 
among various virulence gene 
patterns P0; the absent of gene and P1–P5; the present of one to five genes, respectively. Each data point is the mean OD
595
 of independent triplicates of each 
individual isolates. The line bar (black) represents the median OD595 of each group.
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association between MDR phenotype and the presence of bap 
and ompA genes was found. It is possible that due to OmpA 
being a β-barrel porin, antibiotics may be transferred from the 
periplasm through the outer membrane and then couples with 
inner membrane efflux pumps. We also found that A. bauman-
nii carrying ompA were associated with individual drug resis-
tant phenotype (e.g., cefotaxime, ciprofloxacin, and imipen-
em). This finding is consistent with a previous report which 
indicated that, in A. baumannii ATCC 17978, OmpA was in-
volved in resistance to chloramphenicol, aztreonam and nali-
dixic acid [29]. 
We conclude that in this study we found a high prevalence 
of MDRAB and no difference in its ability to form biofilms 
when compared with non-MDRAB. Our data indicate that 
non-MDRAB strains have the ability to form biofilms, and 
biofilm formation might help these strains adapt or persist 
during infections. The presence of tested virulence genes does 
not seem to be related to biofilm formation of A. baumannii 
on a plastic surface. Interestingly, two of those genes, espe-
cially ompA, was associated with antibiotic resistant pheno-
types. The transcriptional or translational analysis of viru-
lence genes can provide good data to confirm their association 
with biofilm or antibiotic resistance phenotypes which must 
be further analyzed. 
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Table 4. The correlation between the presence of ompA and antibiotic resistance phenotype in all tested Acinetobacter baumannii 
isolates
Antibiotics resistance
All A. baumannii isolates n = 225 (%)
P-value a
ompA– (n=35) ompA+ (n=190)
AMInoglycosIdes
amikacin 17 (48.57) 105 (55.26) 0.468
gentamicin 18 (51.43) 135 (71.05) 0.030*
cepheMs
cefotaxime 22 (62.56) 151 (79.47) 0.048*
ceftazidime 23 (65.71) 162 (85.26) 0.014*
ceftriaxone 22 (62.57) 161 (84.74) 0.004*
cefepime 21 (60.00) 131 (68.95) 0.328
FluoroquInolones
ciprofloxacin 25 (71.43) 165 (86.84) 0.038*
carbapenems
imipenem 20 (57.14) 159 (83.68) 0.001*
meropenem 21 (60.00) 156 (82.11) 0.006*
FolAte pAthwAy InhIbItors
TMX/SXT 19 (54.29) 103 (54.21) 1.000
penIcIllIns + β-lactamase inhibitors
cefoperazone/sulbactam 2 (5.71) 44 (23.16) 0.021*
piperacilin/tazobactam 23 (65.71) 155 (81.58) 0.042*
aP-values were analyzed using Fisher's exact test. Asterisks (*) assign statistical significance results (P < 0.05) between the ompA-
negative and the ompA-positive groups. 
Int. MIcrobIol. Vol. 19, 2016 129VIRULENCE GENES OF A. BAUMANNII
References
1.  Akers KS, Chaney C, Barsoumian A, et al. (2010) Aminoglycoside resis-
tance and susceptibility testing errors in Acinetobacter baumannii-calco-
aceticus complex. J Clin Microbiol 48:1132-1138
2.  Badave GK, Kulkarni D (2015) Biofilm producing multidrug resistant 
Acinetobacter baumannii: An emerging challenge. J Clin Diagn Res 
9:DC08-10
3.  Bitrian M, Solari CM, González RH, Nudel CB (2012) Identification of 
virulence markers in clinically relevant strains of Acinetobacter geno-
species. Int Microbiol 15:79-88
4.  Brossard KA, Campagnari AA (2012) The Acinetobacter baumannii 
biofilm-associated protein plays a role in adherence to human epithelial 
cells. Infect Immun 80:228-233
5.  Brown S, Young HK, Amyes SG (2005) Characterization of OXA-51, a 
novel class D carbapenemase found in genetically unrelated clinical 
strains of Acinetobacter baumannii from Argentina. Clin Microbiol In-
fect 11:15-23
6.  Clinical and Laboratory Standards Institute. Performance Standards for 
Antimicrobial Susceptibility Testing: Twenty-first Informational Supple-
ment M100-S21. CLSI, Wayne, PA, USA, 2011
7.  Djeribi R, Bouchloukh W, Jouenne T, Menaa B (2012) Characterization 
of bacterial biofilms formed on urinary catheters. Am J Infect Control 
40:854-859
8.  Duarte A, Ferreira S, Almeida S, Domingues FC (2016) Clinical isolates 
of Acinetobacter baumannii from a Portuguese hospital: PFGE charac-
terization, antibiotic susceptibility and biofilm-forming ability. Comp 
Immunol Microbiol Infect Dis 45:29-33
9.  Eijkelkamp BA, Stroeher UH, Hassan KA, Elbourne LD, Paulsen IT, 
Brown MH (2013) H-NS plays a role in expression of Acinetobacter 
baumannii virulence features. Infect Immun 81:2574-2583
10.  Gaddy JA, Tomaras AP, Actis LA (2009) The Acinetobacter baumannii 
19606 OmpA protein plays a role in biofilm formation on abiotic sur-
faces and in the interaction of this pathogen with eukaryotic cells. Infect 
Immun 77:3150-3160
11.  Gallant CV, Daniels C, Leung JM, Ghosh AS, Young KD, Kotra LP, Bur-
rows LL (2005) Common beta-lactamases inhibit bacterial biofilm for-
mation. Mol Microbiol 58:1012-1024
12.  Goh HMS, Beatson SA, Totsika M, et al. (2013). Molecular analysis of 
the Acinetobacter baumannii biofilm-associated protein. Appl Environ 
Microbiol l79:6535-6543
13.  Gurung J, Khyriem AB, Banik A, Lyngdoh WV, Choudhury B, Bhat-
tacharyya P (2013) Association of biofilm production with multidrug re-
sistance among clinical isolates of Acinetobacter baumannii and Pseudo-
monas aeruginosa from intensive care unit. Indian J Crit Care Med 
17:214-218
14.  Howard A, O’Donoghue M, Feeney A, Sleator RD (2012) Acinetobacter 
baumannii: An emerging opportunistic pathogen. Virulence 3:243-250
15.  Inchai J, Liwsrisakun C, Theerakittikul T, Chaiwarith R, Khositsakulchai 
W, Pothirat C (2015) Risk factors of multidrug-resistant, extensively 
drug-resistant and pandrug-resistant Acinetobacter baumannii ventila-
tor-associated pneumonia in a Medical Intensive Care Unit of University 
Hospital in Thailand. J Infect Chemother 21:570-574
16.  Lee HW, Koh YM, Kim J, et al. (2008) Capacity of multidrug-resistant 
clinical isolates of Acinetobacter baumannii to form biofilm and adhere 
to epithelial cell surfaces. Clin Microbiol Infect 14:49-54
17.  Liou ML, Soo PC, Ling SR, Kuo HY, Tang CY, Chang KC (2014) The 
sensor kinase BfmS mediates virulence in Acinetobacter baumannii. J 
Microbiol Immunol Infect 47:275-281
18.  Liu Q, Li W, Du X, et al. (2015) Risk and prognostic factors for multi-
drug-resistant Acinetobacter baumannii complex bacteremia: A retro-
spective study in a tertiary hospital of west China. PLoS ONE 
10:e0130701
19.  Loehfelm TW, Luke NR, Campagnari AA (2008) Identification and char-
acterization of an Acinetobacter baumannii biofilm-associated protein. J 
Bacteriol 190:1036-1044
20.  Longo F, Vuotto C, Donelli G (2014) Biofilm formation in Acinetobacter 
baumannii. New Microbiol 37:119-127
21.  McConnell MJ, Actis L, Pachón J (2013) Acinetobacter baumannii: hu-
man infections, factors contributing to pathogenesis and animal models. 
FEMS Microbiol Rev 37:130-155
22.  Misbah S, Hassan H, Yusof MY, Hanifah YA, AbuBakar S (2005). Ge-
nomic species identification of Acinetobacter of clinical isolates by 16S 
rDNA sequencing. Singapore Med J 46:461-464
23.  Naparstek L, Carmeli Y, Navon-Venezia S, Banin E (2014) Biofilm for-
mation and susceptibility to gentamicin and colistin of extremely drug-
resistant KPC-producing Klebsiella pneumoniae. J Antimicrob Che-
mother 69:1027-1034
24.  Qi L, Li H, Zhang C, et al. (2016) Relationship between antibiotic resis-
tance, biofilm formation, and biofilm-specific resistance in Acinetobacter 
baumannii. Front Microbiol 7:483 doi:10.3389/fmicb.2016.00483
25.  Rao RS, Karthika RU, Singh SP, et al. (2008) Correlation between bio-
film production and multiple drug resistance in imipenem resistant clini-
cal isolates of Acinetobacter baumannii. Indian J Med Microbiol 26: 
333-337
26.  Rumbo-Feal S, Gómez MJ, Gayoso C, et al. (2013) Whole transcrip-
tome analysis of Acinetobacter baumannii assessed by RNA-sequencing 
reveals different mRNA expression profiles in biofilm compared to 
planktonic cells. PLoS One 8:e72968
27.  Russo TA, Luke NR, Beanan JM, et al. (2010) The K1 capsular polysac-
charide of Acinetobacter baumannii strain 307-0294 is a major virulence 
factor. Infect Immun 78:3993-4000
28.  Sanchez CJ Jr, Mende K, Beckius ML, Akers KS, Romano DR, Wenke 
JC, Murray CK (2013) Biofilm formation by clinical isolates and the 
implications in chronic infections. BMC Infect Dis 13:47
 doi:10.1186/1471-2334-13-47
29.  Smani Y, Fàbrega A, Roca I, Sánchez-Encinales V, Vila J, Pachón J 
(2014) Role of OmpA in the multidrug resistance phenotype of Acineto-
bacter baumannii. Antimicrob Agents Chemother 58:1806-1808
30.  Suman E, Varghese S, Jose J (2005) Gentamicin resistance in biofilm 
producing Pseudomonas aerruginosa causing catheter associated uri-
nary tract infections. Indian J Med Sci 59:214-216
31.  Tayabali AF, Nguyen KC, Shwed PS, Crosthwait J, Coleman G, Seligy 
VL (2012) Comparison of the virulence potential of Acinetobacter 
strains from clinical and environmental sources. PLoS One 7:e37024
32.  Tomaras AP, Flagler MJ, Dorsey CW, Gaddy JA, Actis LA (2008) Char-
acterization of a two component regulatory system from Acinetobacter 
baumannii that controls biofilm formation and cellular morphology. Mi-
crobiology 154:3398-3409
33.  Vu B, Chen M, Crawford R, Ivanova E (2009) Bacterial extracellular 
polysaccharides involved in biofilm formation. Molecules 14:2535-2554
34.  Wright MS, Iovleva A, Jacobs MR, Bonomo RA, Adams MD (2016) 
Genome dynamics of multidrug-resistant Acinetobacter baumannii dur-
ing infection and treatment. Genome Med 8:1-12 doi:10.1186/s13073-
016-0279-y
35.  Zhang D, Xia J, Xu Y, Gong M, Zhou Y, Xie L, Fang X (2016) Biological 
features of biofilm-forming ability of Acinetobacter baumannii strains 
derived from 121 elderly patients with hospital-acquired pneumonia. 
Clin Exp Med 16:73-80
